Barrington Research analyst James Goss downgrades Fluent (NASDAQ:FLNT) from Outperform to Market Perform.
Nkarta Presents Data Supporting Engineered NK Cell Based Combination Therapies And Next Generation Commercial-Scale Manufacturing Platform At SITC 37th Annual Meeting
Improved Anti-Tumor Activity Demonstrated by the Combination of NKX019 and a CD20-directed Monoclonal Antibody in Preclinical Models
Pulsed Stimulation of NK Cells Derived from Peripheral Blood of Healthy Donors
